feeds

2018

Partnership is a guiding principle for the EMCDDA as it works to increase its understanding of the external dimension of the drug phenomenon and its implications for public health and security in the EU and neighbouring countries. For more than a decade the EMCDDA has been working with countries outside the EU.

2018

This report is part of the EMCDDA-IPA5 project ‘Further preparation of the IPA beneficiaries for their participation with the European Monitoring Centre for Drugs and Drug Addiction’ funded by the European Commission. It provides a top-level overview of the drug phenomenon in Bosnia and Herzegovina, covering drug supply, use and public health problems as well as drug policy and responses. It has been produced with the financial assistance of the European Union.

2018

This report presents the key activities performed by the EMCDDA and Europol in 2017 and the results of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances, including new psychoactive substances notified in 2017, Joint Reports produced, risk assessments conducted and public health-related alerts and advisories issued to the EU Early Warning System Network.

27.07.2018
2018

Every year, on 28 July, the World Health Organization (WHO) and partners mark World Hepatitis Day to increase awareness and understanding of viral hepatitis and the diseases it causes. The day unites patient organisations, governments, medical professionals, civil society, industry and the general public to boost the global profile of viral hepatitis. This year, the WHO will focus on the theme: ‘Test. Treat. Hepatitis’ affirming that timely testing and treatment of viral hepatitis B and C can save lives.

23.07.2018
2018

People in prison experience a higher burden of communicable diseases such as hepatitis B (HBV), hepatitis C (HCV) and HIV often linked to a history of injecting drug use. In addition, incarceration can result in a higher risk of transmission of communicable diseases, due to factors such as overcrowding, poor healthcare facilities and delayed diagnosis.

2018

Compared with the general public, people in prisons have a higher prevalence of infection with blood-borne viruses (BBVs) such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV). This is recognised as a major issue for the health of people in prisons, as well as the general population, because the majority of people who have been incarcerated will subsequently return to their communities.

2018

This evidence-based guidance aims to support the planning and implementation of effective programmes to prevent and control the transmission of infectious diseases in prison settings in the European region. It focuses on three high-burden blood-borne viruses (BBV) in the prison population, namely hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodefciency virus (HIV). The infections caused by these viruses are characterised by the same modes of blood-borne transmission and similar prevention and control interventions.

2018

This evidence-based guidance aims to support the planning and implementation of effective programmes to prevent and control the transmission of infectious diseases in prison settings in the European region. It focuses on three high-burden blood-borne viruses (BBV) in the prison population, namely hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodefciency virus (HIV). The infections caused by these viruses are characterised by the same modes of blood-borne transmission and similar prevention and control interventions.

17.07.2018
2018

EMCDDA Director Alexis Goosdeel today visited his new counterpart at Europol, Ms Catherine De Bolle in the first official meeting between the two heads of agencies.

2018

This publication presents the data and findings of the risk assessment on methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place carfentanil in Schedule I and Schedule IV of the Single Convention on Narcotic Drugs of 1961 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.

2018

This publication presents the data and findings of the risk assessment on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]oxolane-2-carboxamide (THF-F), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place tetrahydrofuranylfentanyl in Schedule I of the Single Convention on Narcotic Drugs of 1961 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.

2018

This publication presents the data and findings of the risk assessment on N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place 4F-iBF in Schedule I of the Single Convention on Narcotic Drugs of 1961 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.

2018

This publication presents the data and findings of the risk assessment on methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place 5F-MDMB-PINACA in Schedule II of the Convention on Psychotropic Substances of 1971 based on a recommendation by the World Health Organization.

2018

This publication presents the data and findings of the risk assessment on N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place AB-CHMINACA in Schedule II of the Convention on Psychotropic Substances of 1971 based on a recommendation by the World Health Organization.

2018

These are the EMCDDA's final annual accounts for the financial year 2017.

25.06.2018
2018

The seventh European drugs summer school (EDSS) — ‘Illicit drugs in Europe: demand, supply and public policies’ — opens today in Lisbon on the eve of International day against drug abuse and illicit trafficking.

2018

The General Report of Activities is an annual publication providing a detailed progress report of the EMCDDA’s activities over a 12-month period. It catalogues the Centre’s achievements in each area of its annual work programme. The report is a useful information source for all those seeking comprehensive information on the Centre and its work.

2018

This report presents the top-level overview of the drug phenomenon in Estonia, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

07.06.2018
2018

In a new update from the EU Early Warning System (EWS) on new psychoactive substances (NPS) (1), the EMCDDA releases today its latest insights in this area entitled Fentanils and synthetic cannabinoids: driving greater complexity into the drug situation.

07.06.2018
2018

Evidence of increased cocaine availability is highlighted by the EMCDDA today in its European Drug Report 2018: Trends and Developments released in Brussels. The development occurs in the context of a dynamic drug market which is able to adapt rapidly in response to drug control measures.

2018

Country Drug Reports provide a top-level overview of the drug phenomenon in European countries, covering topics such as drug supply, drug use and public health problems as well as drug policy and responses. Each Country Drug Report focuses on a single country (28 EU Member States as well as Norway and Turkey, with which the EMCDDA has a special agreement) and is structured thematically. Individual sections are designed so that they may be read in isolation. Country Drug Reports are designed for online viewing but simple PDFs exist for each country.

2018

This report presents the top-level overview of the drug phenomenon in Poland, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Lithuania, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Malta, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in Cyprus, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise.

2018

This report presents the top-level overview of the drug phenomenon in Luxembourg, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise 

2018

This report presents the top-level overview of the drug phenomenon in Finland, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug situation in the United Kingdom, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise. 

2018

This report presents the top-level overview of the drug phenomenon in the Czech Republic, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise.

2018

This report presents the top-level overview of the drug phenomenon in Austria, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2016 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise.

Loading